Dihexa Side Effects & Safety Risks

Understanding Dihexa's potential risks is critical before considering use. This page comprehensively covers reported side effects, theoretical safety concerns, known contraindications, and interactions. The underlying principle is that Dihexa is a pharmacologically active peptide affecting the central nervous system and growth factor signalling—it should be treated with respect and caution, not as a casual supplement.

Anecdotal Reported Side Effects

Community reports of side effects from Dihexa are relatively sparse compared to the number of users, but they do exist. Reported mild effects include:

Commonly Reported

• Mild headaches: Some users report transient headaches, particularly in the first few days of use
• Anxiety or nervousness: A subset of users report increased anxiety, social anxiety, or a "jittery" sensation
• Overstimulation: Feeling mentally "wired," racing thoughts, or difficulty focusing despite cognitive goals
• Sleep disruption: Occasional reports of insomnia or vivid dreams if taken late in the day
• Mood fluctuations: Some reports of subtle mood changes, though the direction (improvement vs. dysphoria) varies by individual

Rarely Reported

• Tachycardia (elevated heart rate): A few anecdotal mentions; unknown if causally related to Dihexa
• Dizziness: Occasional reports of transient dizziness
• Nausea: Uncommon; may reflect GI tolerance issues rather than systemic effects

Context of Mildness

Most reported side effects are mild and transient. The relative rarity of serious adverse event reports contrasts sharply with the theoretical safety concerns outlined below. This discrepancy may reflect: (1) actual safety at typical community doses; (2) under-reporting of mild effects in an unregulated community; (3) selection bias (only people with good tolerance continue use); or (4) a time lag before serious effects emerge.

The c-Met Oncogenic Pathway: A Fundamental Concern

Why There Is Theoretical Cancer Risk

Understanding the c-Met cancer risk requires knowledge of basic cell biology:

What c-Met Does

The c-Met receptor is a tyrosine kinase that activates signalling cascades controlling:

• Cell proliferation (growth and division)
• Cell survival (resistance to apoptosis—programmed cell death)
• Cell motility and invasion
• Angiogenesis (new blood vessel formation)

In normal physiology, c-Met is tightly regulated and plays important roles in development, tissue repair, and some beneficial neuroplasticity. However, uncontrolled c-Met activation is a hallmark of cancer progression.

c-Met in Human Malignancy

c-Met overexpression, mutation, or aberrant activation occurs in a wide spectrum of human cancers, including:

• Gastric cancer
• Lung cancer (particularly non-small-cell lung cancer)
• Hepatocellular carcinoma
• Renal cell carcinoma
• Breast cancer
• Glioblastoma and other CNS tumours
• Colorectal cancer

In these contexts, c-Met activation promotes tumour growth, metastasis, and drug resistance. Pharmaceutical companies have invested billions in c-Met inhibitors as cancer therapeutics precisely because blocking c-Met can slow tumour progression.

The Dihexa Paradox

Dihexa activates c-Met to achieve neuroprotection and cognitive enhancement in neurons and glia. However, if the same c-Met activation occurs in precancerous or dormant cancer cells, it could theoretically promote malignant progression. This is the central paradox: the same mechanism that benefits the brain may pose systemic risk in individuals with latent malignancies or high cancer susceptibility.

Is the Risk Confirmed in Humans?

No human cases of Dihexa-associated cancer have been documented. However, absence of documented cases does not mean the risk is absent. Cancer development is slow (typically years or decades), community Dihexa use is relatively recent and small, and many users may not have long-term follow-up or may not associate a future cancer diagnosis with earlier Dihexa use.

The cancer risk remains theoretical but biologically plausible. Preclinical studies have not definitively ruled out c-Met-mediated oncogenic risk, and no long-term human safety studies exist to provide reassurance.

Data Integrity Problems Compound the Safety Uncertainty

The c-Met cancer concern is not merely theoretical—it is amplified by the failure of the primary human evidence base:

What Was Lost with the Benoist Retraction

The retracted Benoist et al. (2014) study included safety assessments in Alzheimer's disease patients. While the efficacy claims were fabricated, the safety data were also compromised. We cannot now rely on those safety observations. This means:

• We have no documented human safety data from a rigorous clinical trial
• Any safety signals that might have emerged (malignancies, serious adverse events) in the Benoist cohort are unreliable
• We lost the opportunity to assess safety in the population most likely to benefit (older individuals with cognitive decline) and therefore most likely to reveal adverse effects

Athira Pharma False Claims Settlement

The January 2025 settlement of False Claims Act allegations against Athira Pharma (the company developing fosgonimeton, the IV version of this mechanism) for $4 million further underscores systemic integrity problems in this research ecosystem. The settlement related to NIH grant applications that relied on the compromised Benoist data. This indicates federal authorities found credible evidence that:

• False or misleading claims were made to secure federal funding
• Those claims were grounded in the retracted, fabricated Benoist study
• The company's entire development strategy was influenced by fraudulent data

This is not merely a matter of one bad paper—it suggests deeper issues in the scientific and corporate oversight of this compound's development.

Clinical Trial Safety Data: Fosgonimeton Phase 2

The fosgonimeton Phase 2 Parkinson's disease trial provides one of the few systematic safety observations in a clinical population:

Adverse Events in High-Dose Cohort

• 4 out of 10 patients in the high-dose fosgonimeton arm discontinued the trial due to adverse events
• This 40% discontinuation rate due to tolerability is concerning
• Specific adverse events reported included tremor exacerbation, increased hallucinations, and agitation
• While these effects might reflect exacerbation of Parkinson's disease symptoms rather than direct Dihexa-mechanism toxicity, they indicate that CNS-active angiotensin compounds are not benign in symptomatic neurological populations

Implications for Dihexa Use

Fosgonimeton is a related but distinct compound (intravenous, optimized formulation, different pharmacokinetics). However, the mechanism of action is identical—Ang IV signalling and c-Met activation. The high discontinuation rate due to adverse effects in a neurological disease population raises questions about how Dihexa might affect individuals with underlying neurological vulnerability, even if they are currently cognitively intact.

No Long-Term Human Safety Data

This cannot be overstated: Dihexa has never undergone any long-term human safety evaluation.

• Longest documented human exposure: Benoist et al. (2014) enrolled subjects for what was claimed to be a 12-week trial, but these data are now unreliable due to fabrication
• Community use: Anecdotal reports of years of use exist, but these are unstructured observations without systematic health monitoring
• No cancer surveillance: No prospective study has tracked cancer incidence in Dihexa users
• No organ toxicity assessment: Liver, kidney, and other organ function have not been formally evaluated over time
• No neurological outcomes: Long-term neuroimaging, cerebrospinal fluid biomarkers, or advanced cognitive assessments have not been performed
• Unknown delayed effects: Some toxicities emerge only after months or years of exposure (e.g., certain chemotherapy agents cause cardiomyopathy years after treatment)

The absence of long-term safety data is not reassuring. It is a void. Anyone using Dihexa is volunteering for a long-term, uncontrolled safety experiment.

Absolute and Relative Contraindications

Based on Dihexa's mechanism and the theoretical c-Met-mediated cancer risk, certain populations should absolutely avoid Dihexa, and others should use it only with extreme caution:

Absolute Contraindications (Do Not Use)

• Active malignancy: If you have been diagnosed with any active cancer, do not use Dihexa. The c-Met activation could promote tumour progression.
• Precancerous conditions: Conditions such as dysplasia, Barrett's oesophagus, cervical intraepithelial neoplasia, or others with high malignant potential should contraindicate use.
• Immunocompromised state: Individuals with HIV, on immunosuppressive therapy for transplant or autoimmune disease, or with primary immunodeficiency should avoid Dihexa due to unknown immunological effects and cancer risk in this population.
• Pregnancy and nursing: No safety data exist for fetal or neonatal exposure. The c-Met pathway is critical in fetal development; exogenous activation could have teratogenic consequences.

Relative Contraindications (Extreme Caution)

• Strong personal history of cancer: If you have had cancer in the past, the theoretical risk of recurrence or new malignancy is elevated.
• Strong family history of cancer: Genetic predisposition to cancer (BRCA mutations, Lynch syndrome, Li-Fraumeni syndrome, etc.) increases baseline cancer risk; c-Met activation could exacerbate this.
• Age and cancer risk: Cancer incidence rises sharply with age. Individuals over 50–60 initiating Dihexa should understand that any malignancy developing could be coincidental, delayed, or causally related—and causality would be difficult to establish.
• Smoking or heavy alcohol use: These behaviours increase baseline cancer risk; combining them with c-Met activation is speculative but potentially compounding.

WADA Banned Substance Status

For athletes, an additional consideration is anti-doping status:

• Dihexa and angiotensin II receptor modulators have been listed on the World Anti-Doping Agency (WADA) Prohibited Substances List
• The rationale is that these compounds could provide ergogenic (performance-enhancing) effects and are therefore banned in competitive sport
• Athletes should be aware that Dihexa use will result in a failed doping test and potential disqualification or sanctions
• This WADA status actually provides indirect evidence that these compounds have biological effects that could enhance performance—further reinforcing that they are not inert substances

CYP450 Inhibition and Drug Interactions

Dihexa has been reported to inhibit cytochrome P450 enzymes, which are critical for metabolizing a wide range of medications:

What CYP450 Inhibition Means

• If Dihexa inhibits CYP450, it reduces the metabolism of drugs cleared through these pathways
• This leads to accumulation of the drug in the blood, increasing its concentration and potentially toxicity
• The magnitude of effect depends on which CYP enzymes Dihexa inhibits and how much it inhibits them

Potentially Affected Drug Classes

• Statins: Used to lower cholesterol; metabolized by CYP3A4. Inhibition could increase myopathy risk.
• Benzodiazepines: Anti-anxiety medications; many are metabolized by CYP3A4. Inhibition could prolong sedation.
• Antiarrhythmics: Heart rhythm medications; some metabolized by CYP3A4. Elevated levels could cause cardiac effects.
• Anticoagulants: Including warfarin; altered metabolism could affect bleeding risk.
• Antidepressants: Many SSRIs and other psychiatric medications are CYP-metabolized.
• Immunosuppressants: Used in transplant patients; often CYP3A4-dependent.

Evidence for CYP450 Inhibition

The evidence that Dihexa inhibits CYP450 is not definitive. Some anecdotal reports and theoretical discussions mention this concern, but formal in vitro or in vivo studies have not been published. Until this is clarified, anyone taking multiple medications should exercise caution.

Known Drug Interactions: Acetylcholinesterase Inhibitors

One specific interaction has emerged from clinical trial data:

The ACT-AD Finding

The fosgonimeton ACT-AD Phase 2 trial revealed an unexpected finding: acetylcholinesterase (ACh-E) inhibitors—standard Alzheimer's disease medications (donepezil, rivastigmine, galantamine)—appeared to interfere with fosgonimeton's efficacy. Specifically:

• Subgroup analysis suggested that patients co-administered ACh-E inhibitors showed reduced benefit from fosgonimeton
• The mechanism of this interference is unknown
• One hypothesis: ACh-E inhibitors upregulate acetylcholine signalling, which might compete with or antagonize Ang IV/c-Met signalling
• Another hypothesis: Both compounds affect synaptic plasticity through different pathways, and interference could occur at the level of consolidated change

Implications for Dihexa

While this interaction was observed with fosgonimeton in a clinical trial context, Dihexa users who are also taking ACh-E inhibitors (whether prescribed or over-the-counter cholinergic supplements) should be aware that efficacy may be reduced or effects unpredictable. This is another reason to introduce Dihexa one compound at a time and observe carefully.

The Principle: Treat With Respect, Not Casual Optimism

Dihexa is not a dietary supplement like vitamin D or B vitamins. It is a synthetic peptide with a specific mechanism of action affecting central nervous system signalling and growth factor pathways. It activates c-Met, an oncogenic receptor. It may inhibit drug-metabolizing enzymes. It has failed in human clinical trials. Its primary evidence base was retracted due to fabrication.

The appropriate stance is one of cautious respect. Not fear—the theoretical risks have not materialized in documented human cases, and many community users report positive experiences without serious adverse events. But also not the casual optimism that often attends supplement use.

If you are considering Dihexa, consult a healthcare professional. If you use Dihexa, maintain awareness of your health status, any emerging symptoms, and any potential interactions with medications or other compounds. Do not assume safety based on sparse adverse event reporting in an unregulated community. And absolutely do not use Dihexa if you have any personal or family history of cancer, active immunocompromise, or complex medication regimens.

For more information on the research evidence, see our comprehensive research review. For dosage guidance, visit dosage information. For understanding how Dihexa works, consult the mechanism of action page. Information on the related compound fosgonimeton is available at fosgonimeton trials and development. For legal considerations, see legal status in the UK. And for foundational background, visit what is Dihexa.